Cervical Cancer
If it’s your first time on this website, please read the disclaimer section.
May 25 – Jun 01, 2026
Extended-field intensity-modulated radiation therapy and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic or common iliac lymph nodes: a multicenter prospective cohort study.
J GYNECOL ONCOL · Q1 JOURNAL - RANK #14/140
This multicenter prospective cohort study evaluated the efficacy and safety of extended-field intensity-modulated radiotherapy (EF-IMRT) combined with concurrent chemotherapy and high-dose-rate (HDR) brachytherapy in 204 patients with locally advanced cervical cancer and positive para-aortic (PALN) or common iliac lymph nodes (CILN). The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), local progression-free survival (LPFS), distant metastasis-free survival (DMFS), and adverse events. The 3-year and 5-year PFS rates were 68.3% and 64.6%, respectively, while OS rates were 76.4% and 69.5%, and 5-year LPFS and DMFS were 83.1% and 70.1%. The study concluded that EF-IMRT with concurrent chemotherapy was tolerable and effective, with favorable local control and OS outcomes.
10.3802/jgo.2026.37.e114
May 11 – May 18, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.
J GYNECOL ONCOL · Q1 JOURNAL - RANK #14/140
This study assessed the antitumor activity, safety, and exploratory biomarker analyses of trastuzumab deruxtecan (T-DXd) in HER2-expressing gynecologic cancers through the DESTINY-PanTumor02 phase 2 clinical trial. Pretreated patients with locally advanced, metastatic, or unresectable HER2-expressing gynecologic cancers received 5.4 mg/kg of T-DXd, and outcomes such as confirmed objective response rates (ORR), safety, progression-free survival, and overall survival were measured. Investigator-assessed ORRs were 57.5% (endometrial), 50.0% (cervical), and 45.0% (ovarian) cancer cohorts, with safety data revealing interstitial lung disease/pneumonitis occurrence in 10.8% of patients. The findings demonstrate clinically meaningful efficacy of T-DXd and support its use in pretreated HER2-expressing gynecologic cancers, with a manageable safety profile.
10.3802/jgo.2026.37.e65
Apr 20 – Apr 27, 2026
Phase II study of pembrolizumab plus olaparib in recurrent cervical cancer progressing after platinum-based chemotherapy (GOTIC-025).
GYNECOL ONCOL · Q1 JOURNAL - RANK #11/140
This multicenter, investigator-initiated, single-arm phase II trial evaluated pembrolizumab (200 mg every three weeks) plus olaparib (600 mg daily) in immunotherapy-naive patients with recurrent cervical cancer after platinum-based chemotherapy. Twenty-eight patients were enrolled (26 evaluable; 14 squamous histology; 20 with ≥2 prior regimens; 22 previously received bevacizumab); the primary endpoint was objective response rate (ORR), with secondary endpoints of progression-free survival (PFS), overall survival (OS), and safety. ORR was 3.8% (90% CI 0.2–17.0%) and disease control rate was 50.0%, with median PFS 3.4 months; grade ≥3 adverse events occurred in 60.7%, predominantly hematologic, leading to olaparib discontinuation in 4 patients and no pembrolizumab discontinuations. The combination showed manageable safety but limited antitumor activity, suggesting minimal added benefit of PARP inhibition to PD‑1 blockade in this setting.
10.1016/j.ygyno.2026.04.007
Apr 13 – Apr 20, 2026
Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study.
GYNECOL ONCOL · Q1 JOURNAL - RANK #11/140
This multicenter, open-label phase 1b/2 trial (innovaTV 205/ENGOT-cx8/GOG-3024; NCT03786081) evaluated the efficacy and safety of tisotumab vedotin (TV) in combination with carboplatin and/or pembrolizumab (± bevacizumab) in first-line and previously treated recurrent/metastatic cervical cancer across dose-expansion arms D (1L TV+carboplatin), E/F (1L/2L+ TV+pembrolizumab), and H (1L TV+carboplatin+pembrolizumab ± bevacizumab). The primary endpoint was investigator-assessed objective response rate (ORR) per RECIST v1.1; as of October 15, 2025, among 139 enrolled patients, confirmed ORRs (median DOR) were 54.5% (8.6 months), 40.6% (not reached), 35.3% (18.2 months), and 65.8% (13.3 months) in arms D, E, F, and H, respectively. Median progression-free survival was 6.9, 5.3, 5.6, and 10.6 months, and median overall survival was 25.5, 30.7, 15.3, and 28.0 months across arms D–H. Grade ≥3 treatment-related adverse events occurred in 72.7%, 45.5%, 48.6%, and 86.8% of patients and led to TV discontinuation in 24.2%, 24.2%, 34.3%, and 55.3% in arms D–H; with ≥5 years of follow-up, investigators concluded that TV-based doublets demonstrated durable activity with encouraging long-term OS and no new safety signals, while the first-line triplet/quadruplet showed meaningful antitumor activity with expected toxicity.
10.1016/j.ygyno.2026.02.008